Synonyms: SU 5416 | SU5416 | VEGF receptor 2 kinase inhibitor III
Compound class:
Synthetic organic
Comment: Semaxanib was a precursor in the development of the next generation kinase inhibitor ultimately approved as sunitinib.
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use ![]() |
A Phase 2 clinical trial (NCT00009919) investigating semaxanib as a therapy for metastatic kidney cancer was terminated. A single Phase 2I trial for advanced colorectal cancer (NCT00004252) was completed, but further development of the compound was ceased in light of the advances made towards next-generation kinase inhibitors with significantly improved efficacy. |
Mechanism Of Action and Pharmacodynamic Effects ![]() |
Semaxanib targets the VEGF angiogenic pathway by inhibiting endothelial VEGFR1 and VEGFR2 (aka KDR) [2]. This inhibits solid tumour growth by blocking the creation of the new vasculature essential for tumour expansion [2]. |